Published on 22 May 2024 on Simply Wall St. via Yahoo Finance
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?
Key Insights
Regeneron Pharmaceuticals' estimated fair value is US$1,903 based on 2 Stage Free Cash Flow to EquityRegeneron Pharmaceuticals' US$994 share price signals that it might be 48% undervalued Analyst price target for REGN is US$1,042 which is 45% below our fair value estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as an investment opportunity by taking the forecast future cash flows of the company and discounting them back to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.